VIGL NASDAQ
Watertown, MA 02142
US
Vigil Neuroscience, Inc., founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotechnology company concentrating on microglia to develop transformative treatments for neurodegenerative diseases. The firm aims to provide disease-altering therapies for patients, their families, and caregivers affected by both rare and widespread neurological disorders. The company's primary experimental therapy is VGL101, a fully human monoclonal antibody (mAb). This compound is engineered to activate the triggering receptor expressed on myeloid cells 2 (TREM2) and is currently in Phase I clinical trials. VGL101 is being investigated for its potential in treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy, and Alzheimer's disease. Furthermore, Vigil Neuroscience is also advancing an orally administered small molecule designed to act as a TREM2 agonist. This alternative therapeutic approach targets common neurodegenerative conditions associated with impaired microglial function.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Atlas Venture Fund X | D-Return | 1,027,978 | $8.00 | 2025-08-05 |
| Thistle Mary | D-Return | 18,068 | $3.38 | 2025-08-05 |
| Thistle Mary | D-Return | 12,155 | $3.03 | 2025-08-05 |
| Thistle Mary | D-Return | 5,000 | $8.00 | 2025-08-05 |
| Kaufmann Petra | D-Return | 144,000 | $2.19 | 2025-08-05 |